Clinical Trial

Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients

Study acronym: PEMMELA

Active, Not Recruiting Phase 2

Record status

This record was last updated November 5, 2024 (before its estimated December 5, 2024 completion). Its status may not reflect the trial's current state.

Summary

There is no standard second line treatment in malignant pleural mesothelioma (MPM). Pembrolizumab has shown to be active in in small phase II studies in MPM. Its activity however, is limited, with a response rate up to 20%. Since the arrival of nivolumab plus ipilimumab as first line standard of care treatment in mesothelioma, no treatment options are investigated in this group of patients in the second line. So, there is a need for new treatment combinations with drugs that might exhibit a synergistic interaction with pembrolizumab.

Protocol Amendment History 7 amendments

This ClinicalTrials.gov record has been amended 7 times since 2020-02-25; most recent amendment 2024-11-04.

Status change: Recruiting → Active, Not Recruiting 2024-06-25

Status change: Active, Not Recruiting → Recruiting 2023-01-13

Status change: Recruiting → Active, Not Recruiting 2022-08-01

Status change: Not Yet Recruiting → Recruiting 2021-03-02

Trial Details

NCT Number	NCT04287829
Lead Sponsor	The Netherlands Cancer Institute Collaborators: Merck Sharp & Dohme LLC
Conditions	Mesotheliomas Pleural
Enrollment	58 participants
Start Date	2021-03-01
Primary Completion	2024-12-05 (estimated)
Study Completion	2026-03-05 (estimated)
Updated on ClinicalTrials.gov	2024-11-05